{"publisher":"Thymosin Rx","product":"Thymosin peptides","preparedAt":"2026-11-07","reviewStatus":"Research drafts; medical review has not been claimed","facts":[{"label":"Research finding 1","text":"TESTS randomized 1106 adults with sepsis across 22 centers in China;1089 were included in its modified intention-to-treat analysis.","href":"https://pubmed.ncbi.nlm.nih.gov/39814420/"},{"label":"Research finding 2","text":"TESTS reported 28-day mortality of23.4% with thymosin alpha1 versus24.1% with placebo. The published correction gives a hazard ratio of0.97 (95%CI0.76-1.24), without a clear mortality benefit.","href":"https://www.bmj.com/content/389/bmj.r1098"},{"label":"Research finding 3","text":"TESTS found no clear evidence of lower 28-day mortality and no statistically significant difference in secondary or safety outcomes.","href":"https://pubmed.ncbi.nlm.nih.gov/39814420/"},{"label":"Research finding 4","text":"The smaller Resetalpha supplement report described 120 completers and improved SOFA scores with thymosinalpha 1 added to standard care.","href":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11886152/"}],"sources":[{"title":"The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial.","href":"https://pubmed.ncbi.nlm.nih.gov/39814420/"},{"title":"The Reset-α Study: A Double Blind, Randomised, Multi Center, Phase III Trial for the Efficacy and Safety of Thymosin α-1 (Tα1) in Sepsis Patients","href":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11886152/"},{"title":"Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks","href":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks"},{"title":"Correction: The efficacy and safety of thymosin alpha1 for sepsis (TESTS)","href":"https://www.bmj.com/content/389/bmj.r1098"}],"guides":[{"title":"Thymosin alpha-1, beta-4 and TB-500: identify the molecule first","url":"https://thymosinrx.com/research-guides/alpha1-beta4-tb500-identity","description":"A practical identity map that keeps immune, tissue-repair and fragment research from being pooled together.","date":"2026-11-07"},{"title":"Thymosin alpha-1 in cancer research: adjunct signals are not cure claims","url":"https://thymosinrx.com/research-guides/alpha1-cancer-adjunct-trial-reading","description":"Read the metastatic-melanoma combination trial by comparator, endpoint and statistical result.","date":"2026-11-07"},{"title":"Athletes: beta-4 and TB-500 are named in the 2026 prohibited list","url":"https://thymosinrx.com/research-guides/athletes-beta4-tb500-2026","description":"Separate sport eligibility from approval, prescribing and claims about injury recovery.","date":"2026-11-07"},{"title":"Thymosin beta-4 trials: keep eye drops, wound treatment and fragments separate","url":"https://thymosinrx.com/research-guides/beta4-topical-eye-wound-route","description":"A route-specific look at two early beta-4 studies, including negative primary endpoints in the dry-eye trial.","date":"2026-11-07"},{"title":"Thymosin alpha-1 COVID studies: why conflicting results need design context","url":"https://thymosinrx.com/research-guides/covid-study-design-conflicting-results","description":"Compare a small hospitalized randomized trial with a multicenter cohort without turning either into an outpatient or long-COVID claim.","date":"2026-11-07"},{"title":"Thymosin alpha-1 in hepatitis B: what did the randomized comparison test?","url":"https://thymosinrx.com/research-guides/hepatitis-b-dose-comparison-design","description":"Why two active dose groups cannot answer the same question as a placebo or current-treatment comparison.","date":"2026-11-07"},{"title":"Hepatitis C research: thymosin alpha-1 alone and in combination are different interventions","url":"https://thymosinrx.com/research-guides/hepatitis-c-monotherapy-combination","description":"Read a negative pilot study alongside an interferon-combination trial without borrowing benefits across regimens.","date":"2026-11-07"},{"title":"Intravenous beta-4 phase I studies: exposure data are not repair outcomes","url":"https://thymosinrx.com/research-guides/intravenous-beta4-phase1","description":"Understand what healthy-volunteer safety and pharmacokinetic studies can establish, and why they do not validate TB-500.","date":"2026-11-07"},{"title":"Thymosin status: approval, compounding review and product identity are separate checks","url":"https://thymosinrx.com/research-guides/regulatory-record-form-country-product","description":"Read dated FDA records without mistaking a withdrawn nomination, committee discussion or foreign product name for an authorization.","date":"2026-11-07"},{"title":"Reset-alpha and TESTS: biomarkers and survival answer different questions","url":"https://thymosinrx.com/research-guides/reset-alpha-biomarkers-patient-outcomes","description":"Compare a short sepsis trial report with the larger TESTS publication without treating every positive measure as equivalent evidence.","date":"2026-11-07"},{"title":"TESTS: the large thymosin alpha-1 sepsis trial was negative overall","url":"https://thymosinrx.com/research-guides/tests-sepsis-corrected-results","description":"Read the randomized trial with its May 2025 correction, including corrected mortality hazard ratios and limits.","date":"2026-11-07"},{"title":"Thymosin alpha-1 and vaccine antibody research: what was measured?","url":"https://thymosinrx.com/research-guides/vaccine-antibody-endpoint","description":"Why an antibody-response study does not automatically establish fewer infections or a recommendation for vaccine adjunct use.","date":"2026-11-07"}]}